Skip to main content
Clinical Trials/NCT06365047
NCT06365047
Active, not recruiting
Phase 3

Clinical Investigation to Measure the Changes in the Oral Environment Resulting From a 12 Weeks Exposure to an Arginine Containing Toothpaste

Tufts University1 site in 1 country70 target enrollmentAugust 31, 2024

Overview

Phase
Phase 3
Intervention
8% Arginine toothpaste
Conditions
Xerostomia
Sponsor
Tufts University
Enrollment
70
Locations
1
Primary Endpoint
Salivary pH Impact
Status
Active, not recruiting
Last Updated
2 months ago

Overview

Brief Summary

This is a clinical investigation to measure the changes in the oral environment resulting from a 3 month exposure to an arginine containing toothpaste. This study is a double blind, randomized controlled, parallel design. Seventy (70) male and female subjects who meet the inclusion/exclusion criteria will be enrolled in the study. Following oral health evaluations, subjects will be assigned to the treatment schedule and receive their assigned study product.

Registry
clinicaltrials.gov
Start Date
August 31, 2024
End Date
June 1, 2028
Last Updated
2 months ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Male or female volunteers 18- 80 years of age and in general good health.
  • Willing and able to understand and sign the informed consent form.
  • Subjects currently taking at least two medications known to cause xerostomia (dry mouth) as a side effect for the last three months.
  • Be willing to conform to the study protocol and procedures.
  • Polypharmacy subjects must score 4 or more on the VAS scale of 0-10 ("How severe is your dryness right now?").
  • Flow of 5 minutes unstimulated saliva should be below 0.16 ml/min.
  • No known history of allergy to personal care/consumer products or their ingredients, relevant to any ingredients in the test products as determined by the study examiner.
  • Minimum of 10 teeth

Exclusion Criteria

  • Subjects unable to understand or unwilling to sign the informed consent form.
  • Medical condition which requires premedication prior to dental visits/procedure.
  • Active disease of the hard or soft oral tissues.
  • History of salivary gland disease such as Sjogren's syndrome, Sarcoidosis, or Head and Neck Radiation Therapy.
  • Use of antibiotics or antimicrobial drugs within 30 days prior to study start.
  • Participation in any other clinical study within 1 week prior to enrollment into this study.
  • Subjects who must receive dental treatment during the study dates.
  • Immunocompromised individuals (HIV, AIDS, immunosuppressive drug therapy).
  • Presence of orthodontic bands.
  • Current smokers (if former smoker, should have stopped at least 1 month prior to Visit 1)

Arms & Interventions

Investigative Arm- Using an 8% Arginine toothpaste

For the study period (12 weeks), subjects in the Investigative Arm will be instructed to brush their teeth with an 8% Arginine toothpaste.

Intervention: 8% Arginine toothpaste

Control Arm- a 1000 ppm F toothpaste

For the study period (12 weeks), subjects in the Control Arm will be instructed to brush their teeth with Control Arm- a 1000 ppm F toothpaste.

Intervention: 1000 ppm F toothpaste

Outcomes

Primary Outcomes

Salivary pH Impact

Time Frame: 12 weeks

The objective of this clinical research study is to determine if the use of an Arginine containing toothpaste alters the salivary pH of people with xerostomia.

Secondary Outcomes

  • Measuring the change in the oral microbiome(12 weeks)

Study Sites (1)

Loading locations...

Similar Trials